Kim Kelderman, Chief Executive Officer and Director of BIO-TECHNE Corp, filed a Form 4 on November 3, 2026, disclosing a disposition of 2,385 shares of common stock on November 1, 2026, at $72.66 per share.

Key Highlights

  • Transaction: Kelderman disposed of 2,385 shares of BIO-TECHNE Corp common stock on November 1, 2026, under transaction code F (tax withholding).
  • Price per share: The shares were disposed of at $72.66 each.
  • Remaining direct holdings: Following the transaction, Kelderman directly holds 80,509 shares of common stock.
  • Stock options: The filing reports multiple outstanding stock option grants with exercise prices ranging from $52.83 to $120.46, covering a total of 453,480 underlying shares of common stock.
  • Restricted Stock Units: Kelderman holds Restricted Stock Units covering 183,285 shares and Performance Restricted Stock Units covering 121,969 shares, with various vesting schedules.
  • Issuer and exchange: BIO-TECHNE Corp trades on NASDAQ:TECH.

Kelderman November 2026 Share Disposition and Holdings at BIO-TECHNE Corp

According to the Form 4 filed with the SEC on November 3, 2026, Kim Kelderman, who serves as both Chief Executive Officer and Director of BIO-TECHNE Corp (NASDAQ:TECH), reported a single non-derivative transaction. On November 1, 2026, Kelderman disposed of 2,385 shares of common stock at a price of $72.66 per share under transaction code F, which the form associates with shares withheld for tax obligations. Following this transaction, the filing states Kelderman directly owns 80,509 shares of common stock.

The filing also details an extensive set of derivative holdings. Ten stock option grants (rights to buy) are listed, with exercise prices of $52.83, $66.97, $68.54, $74.91, $84.61, $94.52, and $120.46, covering underlying common stock totaling 453,480 shares. Several of those options are reported as fully exercisable, while others have vesting schedules extending through August 2028. Additionally, the filing discloses two tranches of Performance Restricted Stock Units covering 51,261 and 70,708 shares of common stock, respectively, each vesting in full or in part upon achievement of performance goals on August 15, 2027, and August 15, 2028.

Four tranches of time-based Restricted Stock Units are also reported: 8,544 units vesting August 15, 2027; 23,569 units vesting across August 15, 2027, and August 15, 2028; 57,590 units vesting across August 17, 2027, August 17, 2028, and August 17, 2029; and 93,582 units vesting August 17, 2029. The filing was signed by Andrew Nick, Attorney-in-Fact for Kim Kelderman, pursuant to a previously filed power of attorney.

What Was Disclosed

The filing disclosed a tax-withholding disposition of 2,385 common shares at $72.66 by BIO-TECHNE Corp's CEO Kim Kelderman on November 1, 2026, leaving Kelderman with 80,509 directly held shares, plus substantial derivative holdings including stock options and restricted stock units.